Sept 21 (Reuters) – Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes,
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Following is a summary of current sports news briefs. Tennis-WTA Finals to test endurance, nerve…
Despite a slow start, NC State fended off East Tennessee State's upset bid on Friday…
Nov 7 (Reuters) - Russia's delegation to talks with the United States and Ukraine next…
Mumbai (Maharashtra) [India], November 7: Capital India Finance Limited (CIFL), a listed NBFC focused on…
(Updates vote count, adds Seymour quote, paragraphs 1-5) By Lucy Craymer and Alasdair Pal WELLINGTON,…
John Mobley Jr. scored 25 points while Andrija Jelavic and Amare Bynum keyed a second-half…